3 Keys to Watch In Abbott Labs’s Q2 Earnings презентация

fell 2.5% year-over-year in Q1

Operating costs grew, pushing EPS down 30%

Center

Nutritional revenue down 4% year-over-year in Q1

Business is Abbott’s largest by revenue

International sales biggest growth driver

major infant nutrition market, with double-digit percentage annual growth

Other major players have been hit from the recall: Danone’s early life nutrition sales fell 4.8% in most recently reported quarter

Problems in China

Source: Wikimedia Commons

valued at up to $50 billion with 7% annual growth, according to consulting firm Zenith International

International sales are Abbott’s big growth market: International Pediatric Nutritional revenue jumped by 9% in 2013, while International Adult Nutritional sales climbed 8%

Currency issues are likely to impact Abbott’s Q2 results

Nutrition’s Huge Opportunity

a 2.5% currency hit

Diagnostics sales growth has been strong: Abbott has recorded more than 4% revenue growth in each of the past two years

Key #2: Will Diagnostics Keep Up?

Source: Abbott Labs Media Gallery

immunochemistry diagnostics market, Abbott’s major business, is expected to grow at nearly 7% annually through 2018

Abbott is in a tough fight with diagnostics giant Roche: Roche owns more than 30% total market share for diagnostics, with immunochemistry making up around 11% of the Swiss company’s total

Diagnostics: Abbott’s Best Growth Hope?

stent sales dropped 5% YOY in Q1

Currency issues hit hard, costing 2.4% in sales growth

Key #3: Is a Turnaround Coming for Stents?

Asia

Company picked up FDA approval of Supera peripheral stent in late March, but still waiting on an ongoing US trial for the Absorb

Tight hospital budgets and intense competition with rival stent makers like Boston Scientific means that growth likely will be slow to come by in medical devices

Will Investors Be Left Wanting?

the company’s conference call

Company inked $5.3 billion sale of generic drug assets to Mylan over the past weekend

Deal won’t impact results immediately, but is aimed to help Abbott concentrate on growth businesses and to focus generic drugmaking in emerging markets

Bonus Key: Watch for Generics News

its diagnostics boom and close the gap with larger rivals like Roche?

Will Abbott shore up falling revenue from its stents?

Also: Keep an eye on the latest from Abbott’s new deal to sell generic drug assets to Mylan

Plenty of Keys to Keep an Eye On

investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.